- In April 2024, Shockwave Medical, Inc., the leading innovator in intravascular lithotripsy technology, announced the expansion of its global clinical training program with the launch of the "IVL Education Alliance." This initiative is aimed at enhancing physician proficiency and procedural outcomes through hands-on workshops and virtual training sessions. The program underscores Shockwave’s commitment to advancing interventional cardiology education and supporting broader adoption of IVL technology in complex coronary interventions worldwide
- In March 2024, Philips partnered with leading cardiovascular centers in Europe to conduct a multi-center clinical study evaluating the efficacy of its next-generation IVL system in treating peripheral artery disease (PAD). The study is designed to gather real-world data to support expanded indications and regulatory approvals. This move reflects the growing interest in IVL beyond coronary applications and highlights Philips' strategic focus on broadening its cardiovascular product portfolio
- In February 2024, Abiomed, now a part of Johnson & Johnson MedTech, announced its strategic collaboration with hospitals in Japan to integrate coronary IVL into high-risk PCI procedures involving Impella-supported patients. The initiative seeks to optimize outcomes in patients with severe calcified coronary lesions, particularly those with poor left ventricular function. This development signals the increasing synergy between mechanical circulatory support and calcium modification technologies
- In January 2024, CardioFlow Medtech received CE certification for its proprietary IVL balloon catheter, marking its official entry into the European market. This regulatory milestone enables the China-based company to expand internationally and meet the growing demand for innovative, minimally invasive calcium modification tools. The CE approval reflects the rising global interest in alternative IVL systems and increased competition in the segment
- In December 2023, Medtronic plc announced an early-stage investment in a start-up focused on next-generation intravascular lithotripsy platforms with dual-energy delivery capabilities. The collaboration aims to explore novel mechanisms for enhanced plaque modification in highly calcified lesions. This move highlights Medtronic’s strategic intent to diversify its interventional cardiology solutions and capitalize on the growing IVL market segment through innovation and targeted partnerships.
